Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Alzheimer's Disease
Interventions
DRUG

CHF 5074 1x

oral tablet, 1x, once a day in the morning for 12 weeks

DRUG

CHF 5074 2x

oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks

DRUG

CHF 5074 3x

oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks

DRUG

Placebo

oral tablet, once a day in the morning for 12 weeks

Trial Locations (9)

33716

Comprehensive NeuroScience, Inc., St. Petersburg

78757

Senior Adults Specialty Research, Austin

07724

Memory Enhancement Center of America, Inc., Eatontown

08831

Memory Center of New Jersey, Inc., Monroe Twp

08755

Memory Enhancement Center of NJ, Inc., Toms River

Unknown

Clinica Santa Maria, Div Neurologia, Castellanza

Osp. Maggiore Policlinico, Clin. Neurol, Milan

Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milan

Nuovo Osp Civ S. Agostino Estense, Dip di Neuroscienze, Modena

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CERESPIR

INDUSTRY